NASDAQ$ANNX
Annexon Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Annexon reported second quarter 2022 financial results and outlined progress across its broad pipeline.
Annexon reported a net loss of $37.1 million, or $0.96 per share, for the quarter ended June 30, 2022. The company's cash and cash equivalents were $177.6 million as of June 30, 2022, and with the proceeds from a recent financing, they expect to fund operations into the second half of 2025.
- Phase 1 clinical trials initiated for ANX1502 and ANX105.
- FDA granted Fast Track designation to ANX007 for geographic atrophy (GA).
- Final data from Phase 2 clinical trial of ANX005 demonstrated upstream classical complement inhibition associated with clinical benefit in Huntington’s Disease.
- Operating runway extended into the second half of 2025 following $130 million private placement.
Headline financials
Revenue & EPS history
Annexon · Revenue · Quarterly
$400K
Forward guidance
Annexon anticipates several potential catalysts across its pipeline throughout 2022 and 2023.
Tailwinds
- Initial data from its ongoing Phase 2 trial in patients with wAIHA in the second half of 2022
- Data from its ongoing Phase 2/3 trial in patients with GBS in 2023
- Data from its ongoing Phase 2 trial in patients with ALS in 2023
- Initial data from its ongoing Phase 2 trial in patients with GA in the first half of 2023, with additional data after the conclusion of the six-month off-treatment period in the second half of 2023
- Initial data from its Phase 1b trial in patients with lupus nephritis in the second half of 2022, with full data in 2023
Headwinds
- First-in-human data from its ongoing Phase 1 trial of ANX1502 in 2023
- First-in-human data from its ongoing Phase 1 trial of ANX105 in 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+3.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
64%
14 / 22 earnings
Positive
+23.1%
Q1 2022
Best reaction
-8.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.9% | -4.6% | -7.4% | |
| Q3 2025 | -0.7% | -9.1% | +69.1% | |
| Q1 2025 | +9.4% | +8.8% | +37.6% | |
| Q4 2024 | +3.3% | +15.5% | -23.4% | |
| Q3 2024 | -6.6% | -16.6% | -32.2% | |
| Q2 2024 | +3.8% | +11.3% | +12.8% | |
| Q1 2024 | +1.5% | -8.8% | +27.2% | |
| Q4 2023 | +17.6% | +8.0% | -30.9% | |
| Q3 2023 | +16.7% | +22.4% | +23.8% | |
| Q2 2023 | -1.2% | -2.1% | -26.6% | |
| Q1 2023 | +4.2% | +3.7% | -40.7% | |
| Q4 2022 | +3.8% | -8.0% | -15.0% | |
| Q3 2022 | -0.4% | +16.6% | +15.8% | |
| Q2 2022 | +3.1% | +17.2% | +10.2% | |
| Q1 2022 | +23.1% | +25.0% | +51.2% | |
| Q4 2021 | -5.1% | -11.0% | -43.8% | |
| Q3 2021 | +1.3% | +0.2% | -3.4% | |
| Q2 2021 | -4.6% | -13.7% | +11.6% | |
| Q1 2021 | +1.1% | +9.3% | +12.6% | |
| Q4 2020 | -8.1% | -17.4% | -29.5% | |
| Q3 2020 | +3.5% | +9.1% | +13.0% | |
| Q2 2020 | +6.6% | -1.2% | +8.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro